It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e., decubitus having ulcers in a state in which a part of the dermis is deficient, but also severe decubitus that has progressed to stage III to IV according to the NPUAP staging system, particularly decubitus with intractable ulcers with pockets or decubitus with huge intractable ulcers.

A novel therapeutic agent delivery system, methods of use and methods of formation thereof are presented. The novel delivery system is comprised of novel nanoparticles capable of at least partially encapsulating a therapeutic agent such as an anesthetic, antimicrobial, growth factor or protein. The nanoparticles are embedded with in a crosslinked hydrogel. The hydrogel can be administered directly to a patient or may be coated onto a device such as a catheter. The delivery system allows for a sustained release of the therapeutic agent over an extended period of time.

Provided subject matter relates to tissue engineering. More specifically provided are kits, devices and methods for in situ repair and regeneration of guided and functional growth of cells and cell components by providing into the injury site biomaterial solution including the cell(s), magnetic particles and solidifying the biomaterial while applying the magnetic field.

Composite nerve guides for nerve regeneration are provided, wherein the composite guide comprise a nerve graft and a nerve conduit continuing an active agent that promote axon regeneration. The devices can provide structural supports to guide nerve regeneration and locally deliver an active agent (e.g., glial cell-line derived neurotrophic factor (GDNF) and/or glial growth factor 2 (GGF2) to injured nervous system tissue upon implantation in a subject. Methods of treatment using such devices are also provided.

The present invention provides a biological tissue adhesive sheet having excellent tissue adhesiveness. The biological tissue adhesive sheet according to an embodiment of the present invention includes a nonwoven fabric made of fibers containing a crosslinked gelatin derivative, and the gelatin derivative is represented by Formula 1: Gltn-NH-L-CHR.sup.1R.sup.2, wherein Gltn represents a gelatin residue, L represents a single bond or a divalent linking group, R.sup.1 and R.sup.2 are each independently a hydrocarbon group having 1 to 20 carbon atoms or a hydrogen atom, and at least one selected from the group consisting of R.sup.1 and R.sup.2 is the hydrocarbon group.

The disclosure provides bone graft materials, methods for their use and manufacture. Exemplary bone graft materials comprise combining a radiopaque component with a cancellous bone component to produce a bone graft material, wherein the cancellous bone component comprises native osteoreparative cells. Methods for treating a subject with the bone graft material are also provided.

Methods and devices that accelerate and improve graft induced growth of host living cells by application of mechanical tension over the graft/host construct that invites host cells to grow, multiply, and repopulate the graft matrix.

The present invention provides a novel angiogenesis device. The angiogenesis device comprises an angiogenic component and a polymer, and is used to induce angiogenesis at a site for implantation of a cell- or tissue-containing device. The polymer may comprise, for example, at least one or more polyvinyl alcohol resins (A) selected from a modified polyvinyl alcohol resin having an active carbonyl group (A1), a polyvinyl alcohol resin having a triad syndiotacticity of 32 to 40% (A2), and a polyvinyl alcohol resin having a degree of saponification of 97 mol % or more (A3).

The present invention provides a novel angiogenesis device. The angiogenesis device comprises an angiogenic component and a polymer. The polymer may comprise, for example, at least one or more polyvinyl alcohol resins (A) selected from a modified polyvinyl alcohol resin having an active carbonyl group (A1), a polyvinyl alcohol resin having a triad syndiotacticity of 32 to 40% (A2), and a polyvinyl alcohol resin having a degree of saponification of 97 mol % or more (A3).

It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.